Overview

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Status:
Withdrawn

Trial end date:
2021-07-15

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney disease (CKD) stage 3 or 4. Participation in the research study will last up to 21 weeks (about 5 months).

Phase:

Phase 3

Details

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Collaborator:

Janssen Biotech, Inc.